This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MannKind Lands Afrezza Partner but at High Cost

Stocks in this article: MNKDSNY

VALENCIA, Calif ( TheStreet) -- MannKind (MNKD) found a partner willing to sell the inhaled insulin device Afrezza but the deal terms, as expected, are rather terrible. 

Sanofi (SNY), an established Big Pharma player in the global diabetes market, will market Afrezza worldwide in exchange for a $150 million upfront license fee paid to MannKind. The two companies will share Afrezza profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%.

Sanofi agreed to "advance" MannKind up to $175 million for its share of the Afrezza joint venture expenses, meaning MannKind has to repay those costs.

MannKind is also eligible to receive another $775 million in milestone payments from Sanofi tied to regulatory and development target, as well as Afrezza sales achievements. 

Sanofi was always in the mix as a potential Afrezza marketing partner. The company's $8 billion-a-year Lantus insulin franchise is at risk of falling off a cliff with patent protection ending next year. The company was already trying to stave off  generic competition with an improved version of Lantus, so adding Afrezza might also help cushion the blow. 

The "meh" Afrezza FDA label (black box safety warning, onerous post-approval study requirements, no hypoglycemia benefit) combined with MannKind's fragile financial state, put MannKind founder and CEO Al Mann on the defensive when it came to negotiating terms of a marketing partnership.

For all the hype about Afrezza's greatness, Mann walks away with a joint venture in which he secures just one-third of Afrezza's potential profit -- and losses.

Once the initial excitement of a deal getting done washes away, MannKind's current $3 billion-plus valuation will look even more bloated than ever. 

Historically, joint venture marketing partnership for drugs favor the larger partner because they're better equipped to load up expenses and wait out the inevitable losses. The classic example is the Bayer-Onyx Pharma joint venture to sell the cancer drug Nexavar. Onyx ended up hating that partnership -- and so did investors -- because real profits were hard to come by despite strong Nexavar sales. 

Bayer and Onyx shared profits and losses from Nexvar equally and it was considered a terrible deal for the smaller Onyx. MannKind is only getting one-third of the profits and losses of Afrezza, with Sanofi keeping the rest. 

Arena Pharmaceuticals (ARNA) and Eisai partnered to sell the obesity pill Belviq, but Arena gets a royalty from Eisai equal to one-third of Beliviq worldwide sales.

MannKind's Afrezza joint venture partnership with Sanofi is worse, reflecting the risk and uncertainty of the inhaled insulin device's commercial potential. 

If you're looking for something positive, at least MannKind doesn't have to sell Afrezza on its own. 





Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs